Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02429687 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Study acronym: MOGCT-01
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 25, 2023 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv8
  2. Primary completion date: May 2021 to May 2025
    • Study completion date: May 2024 to May 2030
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Study description expanded, about 2 wordsv5
  5. Primary completion date: May 2018 to May 2021
    • Trial status: Enrolling by Invitation to Recruiting
    • Study completion date: May 2020 to May 2024
    • Site details revised
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Active, Not Recruiting to Enrolling by Invitation
    • Eligibility criteria revised
    v3
  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Beihua Kong
3 trials monitored
See all monitored trials
Ovarian Cancer
1,336 trials monitored
See 90 trials at risk
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery.
Trial Details
NCT Number NCT02429687
Lead Sponsor Beihua Kong
Collaborators: Huazhong University of Science and Technology, Zhejiang University, Sun Yat-sen University
Conditions
(from sponsor)		 Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer
Related terms Ovarian Germ Cell Cancer, Ovarian Neoplasms
Enrollment 129 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov